RxDoctor Payments DataLook up a doctor →

Janet Samuels, APRN

Nurse Practitioner · Columbia, MONPI 1134188303

Payments from drug & device makers

$18,877in general payments, 2019–2025

Across 887 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Medtronic$2K
  • Novartis$1K
  • UCB, Inc.$984
  • Boston Scientific$841
  • Pfizer$734
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$190%
  • Travel & lodging$2,27712%
  • Food & beverage$16,30786%
  • Education$2741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)130$2,282
Medtronic21$2,032
Novartis49$1,059
UCB, Inc.39$984
Boston Scientific5$841
Pfizer73$734
EMD Serono, Inc.44$707
Lilly USA, LLC28$626
Biohaven Pharmaceuticals, Inc.40$461
Argenx US, Inc.26$451
Otsuka America Pharmaceutical, Inc.26$408
Eisai Inc.14$399
Sanofi17$368
Avanir Pharmaceuticals, Inc.35$367
Livanova USA, Inc.2$355
SK Life Science, Inc.17$352
Johnson & Johnson(2 entities)10$324
AstraZeneca(2 entities)15$315
Jazz Pharmaceuticals Inc.10$278
Banner Life Sciences, LLC13$275
Biogen13$273
Teva Pharmaceuticals USA, Inc.16$261
TG Therapeutics, Inc.15$261
Amneal Pharmaceuticals LLC13$243
Genentech USA, Inc.12$238
Biohaven Pharmaceutical Holding Company Ltd.17$233
ANI Pharmaceuticals, Inc.9$233
Bristol Myers Squibb18$230
Kyowa Kirin, Inc.14$220
Lundbeck LLC12$217
Alnylam Pharmaceuticals Inc.8$200
Harmony Biosciences LLC6$190
Mallinckrodt Hospital Products Inc.7$183
Amgen10$181
Catalyst Pharmaceuticals, Inc.5$169
Neurocrine Biosciences, Inc.9$160
Acadia Pharmaceuticals Inc8$142
Merz Pharmaceuticals, LLC6$141
CSL Behring4$119
GE HealthCare4$119
Acorda Therapeutics, Inc5$109
Tanabe Pharma America, Inc.6$96
Grifols USA, LLC4$95
Neurelis, Inc.3$69
Axsome Therapeutics, Inc.4$68
Abbott3$63
Xeris Pharmaceuticals, Inc.3$58
Impel Pharmaceuticals Inc.3$58
Supernus Pharmaceuticals, Inc.4$57
Takeda Pharmaceuticals U.S.A., Inc.3$55
Merck3$51
Adamas Pharmaceuticals, Inc.3$51
Nevro Corp.2$45
Almatica Pharma LLC2$45
Chiesi USA, Inc.2$38
Sanofi-aventis U.S. LLC2$32
Novo Nordisk2$29
Averitas Pharma Inc.1$29
Arbor Pharmaceuticals, Inc.2$27
Corium, LLC1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,877 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$129,874
Medicare patients
510
Services billed
5,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate21$143,295
AptiomEslicarbazepine Acetate38$93,718
Nurtec OdtRimegepant Sulfate39$87,119
CopaxoneGlatiramer Acetate15$82,490
AmpyraDalfampridine13$57,305
UbrelvyUbrogepant36$44,219
Aimovig AutoinjectorErenumab-Aooe46$40,536
Lacosamide180$32,797
Emgality PenGalcanezumab-Gnlm36$31,199
BriviactBrivaracetam25$26,385
Dimethyl Fumarate25$26,137
Ajovy AutoinjectorFremanezumab-Vfrm27$21,916
FycompaPerampanel17$20,869
Levetiracetam428$14,297
Rasagiline Mesylate47$13,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$142$143,29521 claims
PfizerNurtec Odt, Dilantin$734$90,66356 claims
Teva Pharmaceuticals USA, Inc.Copaxone$261$82,49015 claims
Acorda Therapeutics, IncAmpyra$109$57,30513 claims
AbbVieUbrelvy, Namzaric$2,282$52,15850 claims
UCB, Inc.Briviact$984$26,38525 claims
Eisai Inc.Fycompa$399$20,86917 claims
Neurelis, Inc.Valtoco$69$9,64111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →